References
- Outpatient Psychiatry Diagnosis and Treatment, A. Lazare. Williams andWilkins, Baltimore 1979; 263
- 340, Note 1
- Janowsky D. S., et al. Methylphenidate hydrochloride effects on psychological tests in acute schizophrenic and nonpsychotic patients. Arch. Gen. Psychiatry February, 1977; 34: 189–194
- McCormick T. C., McNeel T. W. Acute psychosis and Ritalin abuse. Tex. State. J. Med February, 1963; 59: 99–100
- Janowsky D. S., et al. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch. Gen. Psychiatry February, 1973; 28: 185–191
- Janowsky D. S., Davis J. M. Methylphenidate, dextroamphetamine, and levampheta-mine. Arch. Gen. Psychiatry March, 1976; 33: 304–308
- Lazare. 585, Note 1
- Ludwig A. M. Anxiety and substance abuse. Psychiatr. Ann October, 1979; 9: 19–26
- Eaton M. T., Jr., Peterson M. H., Davis J. A. Psychiatry Medical Outline Series3rd ed. Medical Examination Publishing Company, New York 1976; 258
- Fieedman A. M., Kaplan H. I., Sadock B. J. Modern Synopsis of Comprehensive Textbook of Psychiatry II2nd ed. Williams and Wilkins, Baltimore 1976; 962
- Physicians' Desk Reference37th ed., B. B. Huff. Medical Economics Company, Oradell, NJ 1983; 866
- Martin W. R., et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin. Pharmacol. Ther 1971; 12: 245–257
- Goodman and Gilman's: The Pharmacological Basis of Therapeutics5th ed., A. G. Gilman, L. S. Goodman, A. Gilman. Macmillan, New York 1975; 365
- Ditman K. S., et al. Dimensions of the LSD, methylphenidate and chlordiazepoxide experiences. Psychopharmacologia (Berl.) 1969; 14: 1–11
- Lieberman J. A., et al. Methylphenidate challenge as a predictor of relapse in schizophrenia. Am. J. Psychiatry May, 1984; 141: 633–638
- Angrist B., Rotrosen J., Gershon S. Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. Psychopharmacology 1980; 66: 31–38
- Van Kammen D. P., et al. d-Amphetamine-induced heterogenous changes in psychotic behavior in schizophrenia. Am. J. Psychiatry August, 1982; 139: 991–997
- Cadoret R. J., King L. J. Psychiatry in Primary Care. C.V. Mosby, St Louis 1974; 161
- Smith R. C., Davis J. M. Comparative effects of d-amphetamine, 1-amphetmaine, and methylphenidate on mood in man. Psychopharmacology 1977; 53: 1–12
- Current Medical Diagnosis and Treatment, M. A. Krupp, M. J. Chatton. Lange Medical Publications, Los Altos, CA 1981; 631
- Rogers G. A. Methylphenidate interviews in psychotherapy. Am. J. Psychiatry December, 1960; 117: 549–550
- Carey B., Weber M., Smith J. A. Methyl-phenidylacetate hydrochloride (Ritalin) in the treatment of chronic schizophrenic patients. Am. J. Psychiatry December, 1956; 113: 546–547
- Huff. 865, Note 11
- Tollefson G., Lesar T., Teubner-Rhodes D. Anxiety and states benzodiazepines. AFP May, 1983; 27: 151–158
- Stotland N. I., Lesko L. M. Anxiety and its management. Female Patient 1983; 8: 19–34
- Lazare. 255, Note 1
- Janowsky D. S., et al. Comparison of oral and intravenous methylphenidate. Psychopharmacology 1978; 59: 75–78
- Gellhorn A. Violations of human rights: Torture and the medical profession. New Engl. J. Med August, 1978; 299: 358–359
- Angrist B., Rotrosen J., Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 1980; 72: 17–19
- Talley J. H. A useful patient handout in the management of depression. Family Physician May, 1984; 19: 280–283
- Compendium of Drug Therapy, E. S. Geffner. Biomedical Information Corporation, New York 1983–1984; 20, 8
- Table of Commonly Abused Drugs. American Psychiatric Press, Washington, DC, 1, no date
- Eaton, et al. 244, Note 9
- Schedules of Controlled Substances DeA-224a. U.S. Department of Justice, Drug Enforcement Administration, Washington, DC December, 1983; 1
- Siomopoulos V., Seneczko L. O. Heterocyclic antidepressants in nonpsychiatric disorders. AFP March, 1984; 29: 203–208
- A directory of the licensing law. Florida Board of Medical Examiners Newsletter January, 1983; 2: 1–6
- Slovenko R. Psychiatry and Law. Little, Brown, Boston 1973; 47
- 50, Note 37
- Lazate. 583, Note 1
- Special Action Office for Drug Abuse Prevention. Answers the Most Frequently Asked Questions about Drug Abuse. Executive Office of the President; U.S. Government Printing Office, Washington, DC 1972; 15
- 14, Note 40